Actinium Pharmaceuticals, Inc. (ATNM)
NYSEAMERICAN: ATNM · Real-Time Price · USD
1.590
+0.020 (1.27%)
At close: Nov 11, 2026, 4:00 PM EST
1.590
0.00 (0.00%)
Pre-market: Nov 12, 2026, 7:46 AM EST
Actinium Pharmaceuticals Revenue
Actinium Pharmaceuticals had revenue of $35.00M in the quarter ending June 30, 2026. This brings the company's total for the last twelve months to $35.09M. In the year 2025, Actinium Pharmaceuticals had annual revenue of $90.00K. That makes Actinium Pharmaceuticals the 30,364th largest company in the world by revenue and 4,015th in the United States.
Revenue (ttm)
$35.09M
Revenue Growth
n/a
P/S Ratio
1.42
Revenue / Employee
$1,299,630
Employees
27
Market Cap
49.99M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 90.00K | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | 81.00K | -949.00K | -92.14% |
| Dec 31, 2022 | 1.03M | -114.00K | -9.97% |
| Dec 31, 2021 | 1.14M | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
ATNM News
- 1 day ago - Actinium begins enrollment for Radianz clinical trial - TheFly
- 1 day ago - Actinium Pharmaceuticals Announces Enrollment in the RADIANZ Imaging Clinical Trial Intended to Demonstrate the Pan-Cancer Potential of ATNM-400, A First-in-Class HER3-Targeting Radiotherapy - PRNewsWire
- 3 days ago - Actinium forms Scientific Advisory Board - TheFly
- 3 days ago - Actinium Pharmaceuticals Announces Formation of Scientific Advisory Board Featuring Leading Experts in Oncology and Radiopharmaceutical Development - PRNewsWire
- 7 days ago - Actinium Pharmaceuticals Announces Three ASH 2026 Abstracts Highlighting Iomab-ACT Clinical Results in CAR T-Cell Therapy and Sickle Cell Disease - PRNewsWire
- 7 days ago - Actinium Pharmaceuticals Announces ASH 2026 Abstract Highlighting Long-Term Results of Actimab-A in Combination with CLAG-M in Relapsed or Refractory AML - PRNewsWire
- 10 days ago - Actinium Pharmaceuticals Announces Acceptance of ATNM-400 Abstract for Presentation at SABCS 2026 Highlighting Activity Across Therapy-Resistant Breast Cancer Models - PRNewsWire
- 12 days ago - Actinium Pharmaceuticals Announces Inducement Grant to New Employee - PRNewsWire